Zoster‑Associated Ocular Complications
Overview
Herpes zoster ophthalmicus (HZO) refers to reactivation of the varicella‑zoster virus (VZV) in the ophthalmic branch of the trigeminal (cranial nerve V) nerve. When the virus involves ocular structures, a spectrum of inflammatory eye diseases can develop, collectively termed zoster‑associated ocular complications. These complications range from mild conjunctivitis to vision‑threatening conditions such as necrotizing keratitis or optic neuritis.
HZO accounts for roughly 5–10 % of all shingles cases. In the United States, about 1 million people develop shingles each year, and an estimated 15–20 % of those experience ophthalmic involvement [1]. The risk increases sharply after age 50, with incidence ≈ 30 cases per 100,000 person‑years in adults ≥ 60 years old [2]. Immunocompromised individuals (transplant recipients, HIV patients, or those on high‑dose steroids) are also disproportionately affected.
Symptoms
Symptoms usually appear within a few days of the characteristic shingles rash on the forehead or upper eyelid. The following list details common and less‑common ocular manifestations.
- Prodromal pain or burning sensation – often described as “eye itch” or deep forebrain ache.
- Skin rash – vesicular eruptions in the V1 distribution (forehead, scalp, tip of the nose – the “Hutchinson sign”).
- Conjunctivitis – red, watery eye with gritty feeling.
- Keratitis – inflammation of the cornea; may cause blurred vision, photophobia, and a corneal ulcer.
- Epithelial dendritic lesions – branching lesions on the cornea resembling those of herpes simplex.
- Uveitis – inflammation of the iris and ciliary body; can present with eye pain, light sensitivity, and blurred vision.
- Iritis – a form of anterior uveitis with a painful, red eye and possible pupil irregularities.
- Posterior uveitis / choroiditis – inflammation at the back of the eye, causing floaters and decreased central vision.
- Retinitis – necrotizing infection of the retina; may lead to scarring and permanent vision loss.
- Optic neuritis – painful loss of visual acuity and color vision, often accompanied by a relative afferent pupillary defect.
- Acute retinal necrosis (ARN) – a rapidly progressive, sight‑threatening infection of the retina.
- Secondary bacterial infection – can occur if lesions become colonized.
- Dry eye syndrome – due to damage of lacrimal gland innervation.
Causes and Risk Factors
Underlying cause
Varicella‑zoster virus is the same virus that causes chickenpox. After primary infection, VZV remains dormant in dorsal root ganglia. Reactivation—triggered by waning cell‑mediated immunity—produces shingles. When reactivation involves the ophthalmic (V1) division of the trigeminal nerve, viral particles travel along sensory fibers to the eye, initiating inflammation.
Key risk factors
- Age ≥ 50 years – natural decline in VZV‑specific T‑cell immunity.
- Immunosuppression – chemotherapy, organ transplantation, HIV/AIDS, long‑term corticosteroids, biologic agents.
- Physical or emotional stress – may precipitate viral reactivation.
- History of chickenpox or prior shingles – prior infection is required for reactivation.
- Underlying ocular disease – pre‑existing dry eye, glaucoma, or corneal dystrophy may worsen outcomes.
- Vaccination status – lack of shingles vaccination (zoster recombinant vaccine, Shingrix) increases risk.
Diagnosis
Early recognition is essential to prevent permanent vision loss. Diagnosis is primarily clinical, supported by laboratory tests when needed.
Clinical assessment
- Detailed history (onset of rash, pain pattern, prior VZV infection, immunization).
- Full ophthalmic examination: visual acuity, slit‑lamp biomicroscopy, fluorescein staining, intraocular pressure, and dilated fundus exam.
- Check for Hutchinson sign (lesions on the tip of the nose) – strong predictor of ocular involvement.
Ancillary tests
- Polymerase chain reaction (PCR) of tear or lesion fluid – detects VZV DNA with > 95 % sensitivity.
- Viral culture – rarely used because of slower turnaround.
- Anterior segment optical coherence tomography (AS‑OCT) – evaluates corneal thickness and edema.
- Fundus fluorescein angiography (FFA) or indocyanine green angiography (ICGA) – assess retinal vasculitis or choroiditis.
- Serologic testing – VZV IgG may confirm prior exposure but does not differentiate active disease.
Treatment Options
Management combines antiviral therapy, anti‑inflammatory agents, and supportive eye care. Prompt treatment (within 72 hours of rash onset) improves visual outcomes.
Antiviral medications
| Drug | Typical adult dose | Duration | Key notes |
|---|---|---|---|
| Acyclovir | 800 mg orally five times daily | 7–10 days | Renal dose adjustment needed. |
| Valacyclovir | 1 g orally three times daily | 7 days | Better bioavailability; preferred. |
| Famciclovir | 500 mg orally three times daily | 7 days | Alternative if intolerance to others. |
| IV Acyclovir | 10 mg/kg every 8 h | 10–14 days | Used for severe keratitis, retinitis, or immunocompromised patients. |
Corticosteroids
- Topical prednisolone acetate 1 % – every 1–2 hours initially for anterior uveitis; taper over weeks.
- Periocular (sub‑Tenon) or intravitreal steroids – reserved for severe posterior involvement.
- Systemic steroids are sometimes added (e.g., oral prednisone 0.5 mg/kg) to control inflammation, but only after antiviral therapy is established.
Adjunctive therapies
- Artificial tears & lubricating ointments – mitigate dry eye and epithelial breakdown.
- Cycloplegic agents (e.g., atropine 1 %) – relieve ciliary spasm and prevent posterior synechiae.
- Topical antibiotics – prophylaxis against secondary bacterial infection when epithelial defects are present.
- Anti‑viral eye drops (trifluridine) – sometimes used adjunctively, though evidence is limited.
Surgical/Procedural interventions
- Therapeutic keratoplasty – corneal transplantation for non‑healing ulcers or scarring.
- Vitrectomy – indicated for retinal detachment or dense vitreous opacities secondary to ARN.
- Laser photocoagulation – for peripheral retinal necrosis to prevent detachment.
Living with Zoster‑Associated Ocular Complications
Even after the acute phase, patients may experience lingering visual disturbances or dry‑eye symptoms. The following strategies help maintain ocular health.
- Follow‑up schedule – at least weekly visits until inflammation resolves, then monthly for 3–6 months.
- Medication adherence – complete the full antiviral course; do not discontinue steroids abruptly.
- Protective eyewear – wear sunglasses to reduce photophobia and UV‑induced corneal damage.
- Lacrimal substitutes – preservative‑free artificial tears 4–6 times daily; consider punctal plugs if severe.
- Environmental control – avoid smoke, dust, and wind; use a humidifier in dry climates.
- Nutrition – diets rich in omega‑3 fatty acids and antioxidants may support ocular surface health.
- Systemic health – manage diabetes, hypertension, and any immunosuppressive conditions.
- Vaccination – receive the recombinant zoster vaccine (Shingrix) if age‑eligible or immunocompromised.
Prevention
Because HZO results from reactivation, preventing VZV reawakening is the most effective strategy.
- Shingles vaccination – Shingrix (recombinant zoster vaccine) is > 90 % effective at preventing shingles and its ophthalmic complications in adults ≥ 50 years. CDC recommends a two‑dose series 2–6 months apart [3].
- Maintain immune health – adequate sleep, balanced diet, regular exercise, and stress‑reduction techniques.
- Control chronic diseases – optimal glycemic control in diabetes and blood pressure control reduce immunosenescence.
- Avoid unnecessary immunosuppression – when possible, use the lowest effective dose of steroids or immunomodulators.
- Prompt treatment of shingles rash – initiating antivirals within 72 hours can markedly lower the risk of ocular involvement.
Complications
If left untreated or inadequately managed, zoster‑associated ocular disease can lead to:
- Corneal scarring – permanent visual impairment, may require keratoplasty.
- Glaucoma – secondary to trabecular meshwork inflammation or steroid‑induced pressure rise.
- Chronic dry eye – reduced tear production leading to persistent discomfort.
- Retinal detachment – especially after acute retinal necrosis.
- Permanent vision loss – from optic neuritis, macular involvement, or extensive retinal damage.
- Post‑herpetic neuralgia – persistent facial pain that can affect quality of life.
When to Seek Emergency Care
- Sudden loss of vision or marked worsening of visual acuity.
- Severe eye pain unresponsive to oral analgesics.
- Rapidly spreading redness, swelling, or a “white/gray” spot on the cornea.
- Double vision (diplopia) or new onset of flashes and floaters.
- High intra‑ocular pressure symptoms (headache, halos around lights, nausea).
- Fever > 38 °C (100.4 °F) with eye involvement, suggesting systemic spread.
Go to the nearest emergency department or call emergency services (911 in the U.S.) without delay.
**References**
- Mayo Clinic. “Herpes zoster ophthalmicus.” Accessed May 2024. https://www.mayoclinic.org/
- Centers for Disease Control and Prevention. “Shingles (Herpes Zoster) Epidemiology.” 2023. https://www.cdc.gov/
- CDC. “Shingles (Herpes Zoster) Vaccine Recommendations.” 2024. https://www.cdc.gov/
- National Eye Institute. “Herpes Zoster Ophthalmicus.” 2022. https://www.nei.nih.gov/
- Cleveland Clinic. “Viral Eye Infections.” 2024. https://my.clevelandclinic.org/